VEGFA and colorectal carcinoma: The therapeutic response of CRC chemotherapy has recently been improved through the introduction of biological agents targeting vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) axis, such as bevacizumab, aflibercept, and regorafenib (Stivarga®, RG)5,6.